

## ERCEM ATILLASOY, MD

---

### PROFESSIONAL EXPERIENCE

<b>Jazz Pharmaceuticals, Inc.</b> <i>Chief Regulatory &amp; Safety Officer</i>	<b>Philadelphia, PA</b> <i>October 2022-Present</i>
<b>AlloVir, Inc.</b> <i>Chief Regulatory &amp; Safety Officer</i>	<b>Cambridge, MA</b> <i>July 2020-October 2022</i>
<b>Merck &amp; Co., Inc.</b> <i>Vice President, Global Regulatory Affairs and Clinical Safety</i> <i>Executive Director and Therapeutic Area Lead, Vaccines and Infectious Disease</i> <i>Therapeutic Area Lead and Senior Director, Worldwide Regulatory Affairs</i> <i>Senior Director, Global Strategic Regulatory Development</i> <i>Director, Regulatory Liaison, Domestic (General Medicine, Neuroscience, Oncology)</i>	<b>North Wales, PA</b> <i>December 2012- July 2020</i> <i>April 2007- November 2012</i> <i>June 2003- April 2007</i> <i>June 2002- May 2003</i> <i>May 2001- June 2002</i>
<b>Sandoz and Novartis Pharmaceuticals Corporation</b> <i>Medical Director, Internal Medicine, Dermatology, and Infectious Disease</i>	<b>East Hanover, NJ</b> <i>December 1996- April 2001</i>

---

### EDUCATION AND TRAINING

<b>Wistar Institute</b> <i>Research Fellowship, Melanoma, Carcinogenesis and Gene Therapy</i> <i>Dermatology Foundation Research Grants</i>	<b>Philadelphia, PA</b>
<b>University of Pennsylvania Medical Center, Dept. of Dermatology</b> <i>Dermatology Residency</i>	<b>Philadelphia, PA</b>
<b>Yale New-Haven Hospital and Yale University School of Medicine, Dept. of Internal Medicine</b> <i>Medical Internship</i>	<b>New Haven, CT</b>
<b>Yale University School of Medicine</b> <i>Medical Doctorate, Farr Scholar, Class President</i> <i>M.D. Thesis: PTHRP in Human Skin, Leonard Milstone, MD, Advisor</i>	<b>New Haven, CT</b>
<b>City University of New York, Brooklyn College</b> <i>BA/MD Program; BA English Literature; 4.0 GPA; CUNY Belle Zeller Scholar</i>	<b>Brooklyn, NY</b>

---

### INDUSTRY ENGAGEMENT & SCIENTIFIC AFFILIATIONS

- FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC)
  - *Industry Representative selected for a 4-year term, 2019-2023*
- PhRMA Regulatory Steering Group
  - *Senior Merck Representative accountable for overall strategic direction of Science and Regulatory Advocacy activities*
- BIO BioVacRAC
  - *Senior member for Merck; Lead Strategist for Merck's preeminent role at the Annual CBER-BIO roundtable, oversight for Agenda and Merck's presentations and panel participation*

- University of Pennsylvania, Clinical Associate, Voluntary Faculty, Department of Dermatology
- Yale University and Yale School of Medicine Class Officer, Reunion Gift Chair for 2020
- Drug Information Association (DIA)
- DIA Scientific Presenter; Japan DIA (2018)
- Infectious Disease Society of America (IDSA)
- American Board of Dermatology
- American Academy of Dermatology
- American Academy of Pediatrics
- Dermatologists in Industry-member
- State of Pennsylvania, Active Medical License

---

## SELECTED PUBLICATIONS AND PATENTS

- Amitava Mitra and Ercem Atillasoy (2012). Topical Therapies for Psoriasis. In Psoriasis, Jennifer Soung and Bonnie Koo (Ed.)
- Rich P, Harkless LB, Atillasoy ES. Dermatophyte Test Medium Culture for Evaluating Toenail Infections in Patients with Diabetes. *Diabetes Care*, May 23, 2006 (5): 1480-1484
- Atillasoy ES, (Contributor and author) "Skin Cancers and Non-Cancerous Skin Growths," Merck Manual, Home Edition, 2003 edition
- Elewski B, Leyden J, Atillasoy ES. The Infection Confirmation Survey (Onychomycosis). *Archives of Internal Medicine* 2002.
- Jansen DA., Asgari MM, Atillasoy ES, LM Milstone. Clinical and in Vitro Responses of Bilayered Skin Construct (Graftskin) to Meshing. *Arch Dermatol*; June 2002. 138 (6) pp 843-844
- Atillasoy ES, et al. The Role of Anti-Fungal Agents in Immune-Compromised Patients. *Postgraduate Medicine* (in preparation) 2001.
- Hazen KC, Moon AE, and Atillasoy ES. Susceptibility Testing of Anti-Dermatophyte Agents Using a Human Skin Construct. *J Clin Microbiol* 2001.
- Rich P, Karchmer AW, Atillasoy ES. The Efficacy and Safety of Terbinafine in Diabetic Patients: A Multicenter Trial in Toenail Onychomycosis. *Clin Therapeutics* 2001.
- Atillasoy ES, Santoro A, Weinberg JM. Lymphoedema Associated with Kaposi's sarcoma. *J Eur Acad Dermatol Venereol*. July 2001. 15 (4)
- Atillasoy ES (Editor). Use of Terbinafine in the in HIV Positive and Diabetes Patients with Dermatophytosis. *Cutis* (Supplement) July 2001. Vol. 68 1-40S.
- Smith EB, Stein LF, Fivenson DP, and Atillasoy ES. The Safety of Terbinafine in Patients Over the Age of 60 Years: A Multicenter Trial in Onychomycosis of the Feet. *Int J Dermatol*. 2000 Nov; 39(11):861-4.
- Atillasoy ES (editor) Current and Investigative Uses of Graftskin in Wound Care. *Journal Suppl Wounds*. 2000; 12 (5 Suppl A): 1A-79A.
- Atillasoy, ES, Overview of Atopic Dermatitis. Editor Monograph and Slide Set, Novartis Pharmaceuticals, June 1998 – 2000
- Sauter E, Klein-Szanto AJP, Atillasoy ES, Montone KT, Goodrow T, Binder RL, Seykora JT, Herlyn M. Ultraviolet B-Induced Squamous Epithelial and Melanocytic Cell Changes in a Xenograft Model of Cancer Development in Human Skin. *Molecular Carcinogenesis* 23: 168-174, 1998.
- Atillasoy ES, Soballe P, Elenitsas R, Nesbit M, Seykora J, Herlyn M. UVB Induces Atypical Melanocytic Lesions and Melanoma in Human Skin. *Am J Pathology* 152: 1179-1186, 1998
- Weinberg JM, Baxt RD, Egan CL, Rook AH, Atillasoy ES, Regsdale BD. Mucormycosis in a Patient with Acquired Immunodeficiency Syndrome. *Arch Dermatol*. 1997 Feb; 133(2):249-51. No abstract available.
- Atillasoy ES, Elenitsas R, Soballe P, Herlyn M. UVB Induction of Epithelial Tumors in Human Skin Using a RAG-1 Mouse Xenograft Model. *J Invest Dermatol* December 1997.

- Weinberg JM, Baxt RD, Eagan CL, Rook AH, Atillasoy ES, Ragsdale BD. Mucormycosis in a Patient with Acquired Immunodeficiency Syndrome. *Arch Dermatol*. Feb 1997. 133 (2).
- Atillasoy ES, Santoro A, Puri N. Cutaneous Drug Reactions. *Asian Clinics of Dermatol* Vol 2, December 1996.
- Egan C, Atillasoy ES, and Werth V. Case Report: Vulvar Melanoma. CD-ROM, *Am Acad of Dermatol*, 1996.
- Manders S, Heymann WR, Atillasoy ES. Recurrent Toxin-mediated Perineal Erythema. *Arch of Dermatol* 132: 57-60, 1996.
- Atillasoy ES, Weinberg J, et al. Adenocarcinoma of the Breast Presenting as a Keloid. *J. Geriatric Dermatol*, 3(5): 183-185, 1995
- Atillasoy ES. Multicentric Reticulohistiocytosis: Case Report. CD-ROM, *Am Acad of Dermatol*. 1994
- Gaich G, Orloff JJ, Atillasoy ES, Burtis WJ, Ganz MD, Stewart AF. Amino-terminal Parathyroid Hormone-Related Protein: Specific Binding and Cytosolic Calcium Responses in Rat Insulinoma Cells. *Endocrinology* 123(3): 1402-9, 1993
- Schwartz PM, Barnett SK, Atillasoy ES, Milstone LM. Methotrexate Induces Differentiation of Human Keratinocytes. *Proc Natl Acad Sci* 89(2): 594-8, 1992.
- Atillasoy ES, Burtis WJ, Milstone LM. Immunohistochemical Localization of Parathyroid Hormone-related protein (PTHrP) in Normal Human Skin. *J Invest Dermatol* 96(2); 277-80, 1991.
- Atillasoy ES. *Humanities in Medicine*. *JAMA* 262: 9, 1260, 1989
- Nelson JC, Atillasoy ES, Mazure C, Jatlow PI. Hydroxydesipramine in the Elderly. *J Clin Psychopharmacol* 8(6): 428-33, 1988
- Patent Approval via Novartis Pharmaceuticals, Terbinafine for the treatment of Fungal Sinusitis